ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio [Yahoo! Finance]
ProMIS Neurosciences Inc. (PMN)
Company Research
Source: Yahoo! Finance
CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced that the European Patent Office, Japanese Patent Office and IP Australia, the Australian patent office, have recently allowed composition of matter and method of use patent applications related to ProMIS Neurosciences' lead product candidate, PMN310, for the treatment of Alzheimer's disease (AD) (EP 18 835 520.0; JP7448174; AU2022201737). PMN310 is the Company's novel monoclonal antibody that is designed to be highly selective for toxic oligomers of amyloid-beta (Aß), which are believed to be a major driver of AD. The United States Patent and Trademark Office also recently granted US Patent 11,905,317 directed to immunogenic compositions of matter that are being developed for treating AD. Protection
Show less
Read more
Impact Snapshot
Event Time:
PMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PMN alerts
High impacting ProMIS Neurosciences Inc. news events
Weekly update
A roundup of the hottest topics
PMN
News
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies [Yahoo! Finance]Yahoo! Finance
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies [Financial Post (Toronto, Ontario, Canada)]Financial Post
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed AntibodiesGlobeNewswire
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS [Yahoo! Finance]Yahoo! Finance
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS [Financial Post (Toronto, Ontario, Canada)]Financial Post
PMN
Sec Filings
- 4/30/24 - Form 8-K
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- PMN's page on the SEC website